Today is

Department of

Obstetrics and Gynecology

Photo of  Thomas Herzog, MD

Thomas Herzog, MD

Clinical Director University of Cincinnati Cancer Institute and Professor, Obstetrics and Gynecology, UC College of Medicine

Clinical Interest

Gynecologic Oncology
Obstetrics and Gynecology
Oncology

Specialties

Gynecologic Oncology
Obstetrics and Gynecology

Education/Credentials
  • MD: University of Cincinnati College of Medicine
  • BA: Miami University
Board Certifications & Licenses
  • American Board of Obstetrics and Gynecology (Gynecologic Oncology) 04/09/1997
  • American Board of Obstetrics and Gynecology 11/17/1995
Contact Information
  • University of Cincinnati Cancer Institute
  • 3255 Eden Avenue, Suite 250B
  • Cincinnati, Ohio 45019
  • Office 513-558-2177
  • Fax 513-558-2666
  • Email thomas.herzog@uc.edu
  • UC Institute Member Seal

Peer Reviewed Publications

Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381

Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512

Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42

Jackson A.;Eisenhauer E.;Herzog T. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346

Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271

Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589

Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625

Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525

Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254